RxDoctor Payments Data

Cathie Hren, PA

Endocrinology, Diabetes & Metabolism · Grand Junction, CONPI 1356424261

Payments from drug & device makers

$716in general payments, 2019–2025

Across 29 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$122
  • Boston Scientific$73
  • Johnson & Johnson$70
  • Medtronic$67
  • Astellas Pharma US Inc$65
  • AstraZeneca$49
  • plus $271 from 10 others

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$716 in reported general payments places this provider in the 35th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$32,849
Medicare patients
64
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide139$184,324
OzempicSemaglutide119$143,310
Tresiba Flextouch U-200Insulin Degludec100$123,823
TrulicityDulaglutide37$48,644
JardianceEmpagliflozin32$39,346
Tresiba Flextouch U-100Insulin Degludec51$27,237
Fiasp FlextouchInsulin Aspart (Niacinamide)48$22,547
FarxigaDapagliflozin Propanediol29$20,889
Novolog FlexpenInsulin Aspart32$8,021
Nano 2nd Gen Pen NeedlePen Needle, Diabetic44$4,201
Nateglinide64$3,576
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,306
Humalog Kwikpen U-100Insulin Lispro13$2,555
Droplet Pen NeedlePen Needle, Diabetic23$1,612
Metformin Hcl ErMetformin Hcl87$1,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$143,310119 claims
AstraZenecaFarxiga$49$20,88929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

Other endocrinology, diabetes & metabolism in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →